(433 days)
QMAPP® is intended for use by professional healthcare providers for physiological/hemodynamic monitoring. The system may be used to display and analyze surface ECG (Electrocardiogram), respiration, invasive pressures, pulse oximetry (SpO2), End tidal CO2 (EtCO2), fractional flow reserve (FFR), non-invasive blood pressure (NiBP), surface body temperature, cardiac output and intra-cardiac ECG. QMAPP® provides also clinical data acquisition, medical image/data processing and analytical assessment. QMAPP® is intended for use in the areas of, but not limited to cardiology, cardiac catheterization, electrophysiology, radiology, invasive radiology. QMAPP® can be used standalone and in networked environments. The system is intended for patient/procedural data management, such as documentation, logging, reporting, trending, storing, reviewing, carrying out clinical calculations and exporting various representations of the acquired data. Data may also be acquired from and/or send to other devices, such as physiological monitoring system, information management systems, image acquisition/storage devices and other medical devices.
The QMAPP® system offers a complete physiological/hemodynamic monitoring and reporting system. The system is built from three units: an Amplifier, Live Monitoring CPU and Reporting CPU. The Amplifier Unit has various sensors connected with the patient, e.g. ECG, SpO2 and NiBP. The Amplifier Unit is connected to the Live Monitoring CPU via a dedicated Ethernet connection. The acquired patient information can be visualized on a Live Monitoring CPU. Typically located in the technical room. A software application executed on the Live Monitoring CPU can visualize the patient information. Also the Amplifier Unit can be controlled, i.e. most importantly, to set acquisition and filtering parameters for the different sensors, by the Live Monitoring CPU. Optionally the Monitoring unit can be connected via a dedicated Ethernet connection to a Reporting CPU, typically located in the technical room. On the Reporting CPU a database is installed which facilitates data storage and retrieval. A software application executed on the Reporting CPU serves as a patient data management system. It can e.g. be used for analysis, calculation and reporting in various representations of patient information.
The QMAPP® system, can operate standalone or it can be part of a typical hospital network infrastructure. The latter offers the possibility to send or receive information from and to other devices. The software has several communication modules, based on HL7 or DICOM protocols to interface with third party equipment/systems.
• The QMAPP® system works with 3rd party 510(k) cleared SpO2 module (Covidien Nellcor, K083325), NiBP module (CAS Medical Systems, MAXNIBP ND+, e.g. used in FDA cleared device CAS Medical Systems, 740 Select, K150620) and EtCO2 sensors e.g. used in FDA cleared device CLEO Patient Monitor, K142244.
The provided FDA 510(k) Clearance Letter for the QMAPP® System describes the device, its intended use, and a summary of non-clinical tests conducted to support its substantial equivalence. However, the document does not contain the specific details required to fully address your request regarding acceptance criteria and the comprehensive study that proves the device meets them.
Here's a breakdown of what can and cannot be extracted from the provided text, and where the requested information is missing:
Information Present in the Document:
- Overall Device Performance: The "NON-CLINICAL TESTS" section lists various characteristics on which "Bench testing" was carried out, implicitly suggesting these are areas where performance was evaluated. The "Referenced Standards and Performance Testing" section explicitly states that the QMAPP® system "meets the requirements of following performance Standards."
- Study Type: The studies mentioned are "Bench testing," "Usability Testing," and "Software verification and validation testing." The clearance is based on a "Traditional 510(k)" and relies on "non-clinical data."
- Ground Truth Type (for non-clinical testing): For the performance characteristics listed (ECG, Heart rate, SpO2, NiBP, IBP, Cardiac Output, Intra cardiac ECG, Skin Temperature, ECG impedance for Rate of respiratory effort, Measurement accuracy), the "ground truth" would be established by the physical standards and reference systems used during bench testing for each specific measurement. For example, a calibrated heart rate simulator would provide the ground truth for heart rate accuracy.
- Sample Size for Training Set: Not explicitly mentioned, but the document refers to a "software verification and validation testing," implying a dataset (likely synthetic or previously collected) was used.
- How Ground Truth for Training Set was Established: Not explicitly mentioned.
Missing Information (Crucial for your request):
The document focuses on demonstrating substantial equivalence to predicate devices through technical characteristics and adherence to recognized standards. It does not present a detailed study report with specific acceptance criteria, reported performance against those criteria, or the methodology of how "ground truth" was established for clinical or test datasets in the manner you've requested for an AI/ML context.
The QMAPP® system is a physiological/hemodynamic monitoring system, not specifically an AI/ML device that requires a comparison of algorithmic output against expert consensus on a test set, multi-reader multi-case studies, or standalone algorithm performance. The "clinical data acquisition, medical image/data processing and analytical assessment" mentioned are functions of the system, but the document does not elaborate on an AI/ML component with associated performance metrics.
Based on the provided text, here is what can be inferred and explicitly stated, with clear indications of missing information for your request:
1. Table of Acceptance Criteria and Reported Device Performance
The document states that the QMAPP® system was tested against and "meets the requirements of following performance Standards." These standards themselves contain detailed acceptance criteria for various parameters. The table below excerpts the performance characteristics mentioned in the "SUBSTANTIAL EQUIVALENCE SUMMARY TABLE" and "NON-CLINICAL TESTS" sections. Crucially, the document does not provide the specific numerical acceptance criteria (e.g., minimum accuracy percentages, maximum deviations) or the actual measured performance values against those criteria in a consolidated table. Instead, it states that the device "meets the requirements" of the listed standards and has "Accuracy" values which are the specifications for the device itself, not acceptance criteria of a study.
| Acceptance Criteria (via referenced standards & device specs) | Reported Device Performance (as stated in 510(k) summary) |
|---|---|
| Electrocardiograph (ECG) | Tested via Bench Testing; Meets IEC 60601-2-27:2016 |
| ECG Resolution | 24 bit |
| ECG Input impedance | > 2.5 MOhm |
| ECG Common mode rejection | > 100 dB |
| ECG Sampling frequency | 2 – 32 KHz |
| ECG Channels | 12 |
| Heart Rate | Tested via Bench Testing; Meets performance standards |
| HR Method | QRS detection |
| HR Range | 15 – 300 bpm |
| HR Accuracy | ± 2% |
| Respiration Effort | Tested via Bench Testing; Meets performance standards |
| Respiration Method | Impedance Pneumography |
| Respiration Resolution | 1/min |
| Respiration Range | 0 – 150 / Min |
| Respiration Channels | 1 |
| Non-Invasive Blood Pressure (NiBP) | Tested via Bench Testing; Meets IEC 80601-2-30:2018 |
| NiBP Method | Oscillometric (CAS Max module) |
| NiBP Range | 15 - 260 mm Hg |
| NiBP Accuracy | ± 5 mm Hg |
| Oxygen Saturation (SpO2) | Tested via Bench Testing; Meets ISO 80601-2-61:2017 |
| SpO2 Method | Nellcor Oximax |
| SpO2 Range | 1 - 100% |
| SpO2 Accuracy | ± 1% |
| SpO2 Channels | 1 |
| Invasive Blood Pressure (IBP) | Tested via Bench Testing; Meets IEC 60601-2-34:2011 |
| IBP Method | Pressure transducer |
| IBP Accuracy | ± 2 mm Hg or ± 1 % |
| IBP Range | -30 - 320 mm Hg |
| IBP Channels | 4 |
| Skin Temperature | Tested via Bench Testing; Meets ISO 80601-2-56:2017 |
| Skin Temp Method | Thermistor, YSI compatible |
| Skin Temp Range | 20° – 45° C (68° – 113° F) |
| Skin Temp Accuracy | ± 0.1° C (± 0.18° F) |
| Skin Temp Channels | 2 |
| Cardiac Output | Tested via Bench Testing; Meets performance standards |
| CO Method | Thermo Dilution and (calculated) FICK |
| CO Range | 0.1 – 20 L |
| CO Accuracy | ± 0.1 L |
| End Tidal CO2 (EtCO2) | Tested via Bench Testing; Meets performance standards |
| EtCO2 Method | Low flow Side stream |
| EtCO2 Resolution | 0.1 mm Hg (0-49), 0.2 mm Hg (49-152) |
| EtCO2 Accuracy | 0-40 mmHg, ± 2 mmHg; 41-70 mmHg, ± 5%; 71-100 mmHg, ± 8%; >101 10% |
| Intra cardiac ECG | Tested via Bench Testing; Meets performance standards |
| Intra Cardiac ECG Method | Electro Physiology catheter |
| Intra Cardiac ECG Resolution | 24 Bit |
| Intra Cardiac ECG Input impedance | > 2.5 MOhm |
| Intra Cardiac ECG Common mode rejection | > 100 dB |
| Intra Cardiac HR range | 15 – 300 bpm |
| Intra Cardiac Sampling frequency | 2 - 32 kHz |
| Intra Cardiac Channels | 8, 16 or 32 (bipolar) Channels |
| Other General Performance | |
| Electromagnetic compatibility (EMC) | Meets IEC 60601-1-2:2014 |
| Electrical safety testing | Meets AAMI/ANSI EC 60601-1:2005/(R)2012 & A1:2012 C1:2009/(R)2012 & A2:2010/(R)2012 |
| Mechanical safety testing | Meets AAMI/ANSI EC 60601-1:2005/(R)2012 & A1:2012 C1:2009/(R)2012 & A2:2010/(R)2012 |
| Software verification and validation testing | Conducted |
| Usability Testing | Conducted |
2. Sample size used for the test set and the data provenance
- Sample Size for Test Set: Not specified. The document only mentions "Bench testing," "Usability Testing," and "Software verification and validation testing." These are typically performed in a lab environment.
- Data Provenance (e.g., country of origin of the data, retrospective or prospective): Not specified. Given it's bench testing, actual patient data provenance is not directly relevant for the stated tests, but the data used for software verification and validation testing (if involving patient data) is not detailed.
3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts
- Number of Experts & Qualifications: Not applicable/not specified. For bench testing of physiological monitoring devices, the "ground truth" comes from calibrated testing equipment and reference signals, not expert human interpretation in the way, for example, a radiology AI would be evaluated. The "Software verification and validation testing" is also not described as relying on expert review of a patient dataset for ground truth.
4. Adjudication method (e.g. 2+1, 3+1, none) for the test set
- Adjudication Method: Not applicable/not specified. This methodology is typically used when comparing an algorithm's output to human expert interpretations, which is not the type of testing described for this physiological monitor.
5. If a multi-reader multi-case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance
- MRMC Study: Not applicable. The QMAPP® system is described as a physiological/hemodynamic monitoring, data acquisition, and analytical assessment system. It is not presented as an AI-assisted diagnostic tool designed to improve human reader performance in interpreting images or complex clinical scenarios.
6. If a standalone (i.e. algorithm only without human-in-the loop performance) was done
- Standalone Performance: The described "Bench testing" and "Software verification and validation testing" can be considered "standalone" in the sense that they evaluate the device's inherent measurement and processing capabilities without a human in the loop for interpretation, but for a physiological monitor, the ultimate "human-in-the-loop" is the clinician using the displayed information. The document does not describe an AI algorithm that operates entirely independently to make a diagnosis or prediction in the same way an AI for image analysis might.
7. The type of ground truth used (expert consensus, pathology, outcomes data, etc)
- Type of Ground Truth: For the "Bench testing" of physiological parameters, the ground truth would be established by calibrated reference standards and simulated physiological signals. For instance, a signal generator provides a known ECG waveform or blood pressure reading, and the device's measurement is compared to this known input.
8. The sample size for the training set
- Sample Size for Training Set: Not specified. The document mentions "Software verification and validation testing," which would involve a dataset, but its size is not detailed. There is no mention of a "training set" in the context of an AI/ML model, as the device is not presented as such.
9. How the ground truth for the training set was established
- How Ground Truth for Training Set was Established: Not specified. If a "training set" was used for software validation (e.g., for signal processing algorithms), the ground truth would likely be established through
- Synthetic data: Ground truth is known by design.
- Previously validated physiological data: Data collected with highly accurate reference devices, where the "truth" for various physiological parameters is established by the reference device's measurements.
In summary: The FDA 510(k) clearance document for the QMAPP® System confirms that the device meets relevant performance standards through non-clinical bench testing and software validation. However, it does not provide the detailed acceptance criteria and study particulars, particularly those related to expert-adjudicated test sets, MRMC studies, or specific AI/ML training/testing methodologies, because the device is presented as a traditional physiological monitor, not an AI-powered diagnostic system.
FDA 510(k) Clearance Letter - QMAPP® System
Page 1
U.S. Food & Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993
www.fda.gov
Doc ID # 04017.08.00
August 27, 2025
Fysicon BV
℅ Patsy Trisler
Consultant and Official Correspondent
Trisler Consulting
306 Turnberry Court
Lebanon, Indiana 46052
Re: K241766
Trade/Device Name: QMAPP® (Hemo, Hemo Lite, PCM, GO, Hybrid)
Regulation Number: 21 CFR 870.2300
Regulation Name: Cardiac Monitor (Including Cardiotachometer And Rate Alarm)
Regulatory Class: Class II
Product Code: MWI, DQK
Dated: December 9, 2024
Received: December 9, 2024
Dear Patsy Trisler:
We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Page 2
K241766 - Patsy Trisler Page 2
Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device" (https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download).
Your device is also subject to, among other requirements, the Quality System (QS) regulation (21 CFR Part 820), which includes, but is not limited to, 21 CFR 820.30, Design controls; 21 CFR 820.90, Nonconforming product; and 21 CFR 820.100, Corrective and preventive action. Please note that regardless of whether a change requires premarket review, the QS regulation requires device manufacturers to review and approve changes to device design and production (21 CFR 820.30 and 21 CFR 820.70) and document changes and approvals in the device master record (21 CFR 820.181).
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050.
All medical devices, including Class I and unclassified devices and combination product device constituent parts are required to be in compliance with the final Unique Device Identification System rule ("UDI Rule"). The UDI Rule requires, among other things, that a device bear a unique device identifier (UDI) on its label and package (21 CFR 801.20(a)) unless an exception or alternative applies (21 CFR 801.20(b)) and that the dates on the device label be formatted in accordance with 21 CFR 801.18. The UDI Rule (21 CFR 830.300(a) and 830.320(b)) also requires that certain information be submitted to the Global Unique Device Identification Database (GUDID) (21 CFR Part 830 Subpart E). For additional information on these requirements, please see the UDI System webpage at https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/unique-device-identification-system-udi-system.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems.
For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-
Page 3
K241766 - Patsy Trisler Page 3
assistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
Stephen C. Browning -S
LCDR Stephen Browning
Assistant Director
Division of Cardiac Electrophysiology,
Diagnostics, and Monitoring Devices
Office of Cardiovascular Devices
Office of Product Evaluation and Quality
Center for Devices and Radiological Health
Enclosure
Page 4
Food and Drug Administration
Indications for Use
Form Approved: OMB No. 0910-0120
Expiration Date: 07/31/2026
See PRA Statement below.
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Submission Number (if known): K241766/S001
Device Name: QMAPP® (Hemo, Hemo Lite, PCM, GO, Hybrid)
Indications for Use (Describe)
QMAPP® is intended for use by professional healthcare providers for physiological/hemodynamic monitoring. The system may be used to display and analyze surface ECG (Electrocardiogram), respiration, invasive pressures, pulse oximetry (SpO2), End tidal CO2 (EtCO2), fractional flow reserve (FFR), non-invasive blood pressure (NiBP), surface body temperature, cardiac output and intra-cardiac ECG.
QMAPP® provides also clinical data acquisition, medical image/data processing and analytical assessment.
QMAPP® is intended for use in the areas of, but not limited to cardiology, cardiac catheterization, electrophysiology, radiology, invasive radiology.
QMAPP® can be used standalone and in networked environments. The system is intended for patient/procedural data management, such as documentation, logging, reporting, trending, storing, reviewing, carrying out clinical calculations and exporting various representations of the acquired data. Data may also be acquired from and/or send to other devices, such as physiological monitoring system, information management systems, image acquisition/storage devices and other medical devices.
☒ Prescription Use (Part 21 CFR 801 Subpart D) ☐ Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services
Food and Drug Administration
Office of Chief Information Officer
Paperwork Reduction Act (PRA) Staff
PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
Page 5
Submitter: QMAPP®
Fysicon BV Premarket Notification: Traditional 510(k)
510(k) Summary Page 1 of 11
510(k) SUMMARY – QMAPP® – K241766-S001
SUBMITTER
| Submitter Name: | Fysicon B.V. |
|---|---|
| Submitter Address: | Hoogheuvelstraat 114, 5349 BA Oss, The Netherlands |
| Contact Person: | C.W.A. (Eric) van Antwerpen |
| Telephone #: | +31 412 653333 |
| Date Prepared: | 25 July 2025 |
DEVICE
| Device Trade Name: | QMAPP® (Hemo, Hemo Lite, PCM, GO, Hybrid) |
|---|---|
| Common and Classification Name(s): | Monitor, Physiological, Patient (Without Arrhythmia Detection Or Alarms) |
| Classification #: | 21 CFR 870.2300, 21 CFR 870.1425 |
| Product Code | MWI, DQK |
| Regulatory Class | 2 |
| Review Panel | Cardiovascular |
PREDICATE DEVICE
| Primary Predicate Device | K170032, QMAPP® |
|---|---|
| Secondary Predicate Device | K131497, McKesson CardiologyTM Hemo |
DEVICE DESCRIPTION
The QMAPP® system offers a complete physiological/hemodynamic monitoring and reporting system. The system is built from three units: an Amplifier, Live Monitoring CPU and Reporting CPU. The Amplifier Unit has various sensors connected with the patient, e.g. ECG, SpO2 and NiBP. The Amplifier Unit is connected to the Live Monitoring CPU via a dedicated Ethernet connection. The acquired patient information can be visualized on a Live Monitoring CPU. Typically located in the technical room. A software application executed on the Live Monitoring CPU can visualize the patient information. Also the Amplifier Unit can be controlled, i.e. most importantly, to set acquisition and filtering parameters for the different sensors, by the Live Monitoring CPU. Optionally the Monitoring unit can be connected via a dedicated Ethernet connection to a Reporting CPU, typically located in the technical room. On the Reporting CPU a database is installed which facilitates data storage and retrieval. A software application executed on the Reporting CPU serves as a patient data management system. It can e.g. be used for analysis, calculation and reporting in various representations of patient information.
Page 6
Submitter: QMAPP®
Fysicon BV Premarket Notification: Traditional 510(k)
510(k) Summary Page 2 of 11
The QMAPP® system, can operate standalone or it can be part of a typical hospital network infrastructure. The latter offers the possibility to send or receive information from and to other devices. The software has several communication modules, based on HL7 or DICOM protocols to interface with third party equipment/systems.
• The QMAPP® system works with 3rd party 510(k) cleared SpO2 module (Covidien Nellcor, K083325), NiBP module (CAS Medical Systems, MAXNIBP ND+, e.g. used in FDA cleared device CAS Medical Systems, 740 Select, K150620) and EtCO2 sensors e.g. used in FDA cleared device CLEO Patient Monitor, K142244.
| PHYSICAL DESCRIPTION | QMAPP® Amplifier dimensions: 298 x 233 x 47 mm, Weight +/- 2200g, Power External 24 VDC |
|---|
| INTENDED USE / INDICATIONS FOR USE | QMAPP® is intended to be used by professional healthcare providers for physiological/hemodynamic monitoring. The system may be used to display and analyze surface ECG (Electrocardiogram), respiration, invasive pressures, pulse oximetry (SpO2), End tidal CO2 (EtCO2), fractional flow reserve (FFR), non-invasive blood pressure (NiBP), surface body temperature, cardiac output and intra-cardiac ECG. QMAPP® provides also clinical data acquisition, medical image/data processing and analytical assessment. QMAPP® is intended for use in the areas of, but not limited to cardiology, cardiac catheterization, electrophysiology, radiology, invasive radiology. QMAPP® can be used standalone and in networked environments. The system is intended for patient/procedural data management, such as documentation, logging, reporting, trending, storing, reviewing, carrying out clinical calculations and exporting various representations of the acquired data. Data may also be acquired from and/or send to other devices, such as physiological monitoring system, information management systems, image acquisition/storage devices and other medical devices. |
|---|
| SUMMARY OF TECHNOLOGICAL CHARACTERISTICS | The QMAPP® system offers vital signs measuring, visualization, monitoring and analysis. The QMAPP Amplifier offers Surface ECG (Electrocardiogram), respiration, invasive pressures, pulse oximetry (SpO2), end tidal CO2 (EtCO2), Respiration effort, non-invasive blood pressure (NiBP), surface body temperature, cardiac output and intra-cardiac ECG measurements. Typically made in areas of, but not limited to |
|---|
Page 7
Submitter: QMAPP®
Fysicon BV Premarket Notification: Traditional 510(k)
510(k) Summary Page 3 of 11
cardiology, cardiac catheterization, electrophysiology, radiology, invasive radiology.
The vital signs data is transferred to a Live Monitoring CPU, which offers visualization of the vital sign information. The vital signs information can also be transferred to a Reporting CPU, which offers data storage, connection to Hospital Information Systems and PACS. The Reporting CPU also offers vital signs analysis and reports capabilities.
NON-CLINICAL TESTS
Bench testing was carried out on the following characteristics:
- Electrocardiograph (ECG)
- Heart rate
- SpO2
- NiBP
- IBP
- Cardiac Output
- Intra cardiac ECG
- Skin Temperature
- ECG impedance for Rate of respiratory effort
- Measurement accuracy
- Electromagnetic compatibility (EMC)
- Electrical safety testing
- Mechanical safety testing
- Software verification and validation testing
Usability Testing In addition to the above, usability testing was also conducted.
Referenced Standards and Performance Testing The QMAPP® system was tested and meets the requirements of following performance Standards.
- AAMI/ANSI EC 60601-1:2005/(R)2012 & A1:2012 C1:2009/(R)2012 & A2:2010/(R)2012 Medical electrical equipment - General requirements for basic safety and essential performance.
- IEC 60601-1-2:2014 Medical electrical equipment - Part 1-2: General requirements for safety – Collateral standard: Electromagnetic compatibility – Requirements and tests.
- IEC 60601-2-27:2016 Medical Electrical Equipment - Part 2-27: Particular Requirements for The Basic Safety and Essential Performance of Electrocardiographic Monitoring Equipment.
- IEC 80601-2-30:2018 Medical Electrical Equipment - Part 2-30: Particular Requirements for The Basic Safety and Essential Performance of Automated Non-Invasive Sphygmomanometers.
- IEC 60601-2-34:2011 Medical Electrical Equipment - Part 2-34: Particular Requirements for The Basic Safety, Including Essential Performance, Of Invasive Blood Pressure Monitoring Equipment.
Page 8
Submitter: QMAPP®
Fysicon BV Premarket Notification: Traditional 510(k)
510(k) Summary Page 4 of 11
- ISO 80601-2-56:2017 Medical Electrical Equipment - Part 2-56: Particular Requirements for Basic Safety and Essential Performance of Clinical Thermometers for Body Temperature Measurement.
- ISO 80601-2-61:2017 Medical electrical equipment -- Part 2-61: Particular requirements for basic safety and essential performance of pulse oximeter equipment.
| CONCLUSION | The following comparison table shows the similarities and differences in technological characteristics. None of the differences raise new questions of safety and effectiveness. The non-clinical data support the safety of the device and the hardware and software verification and validation testing demonstrate that the QMAPP® system should perform as intended in the specified use conditions. |
|---|
| STATEMENT OF SUBSTANTIAL EQUIVALENCE | The information and data provided in this Traditional 510(k) establish that the modified device is substantially equivalent in the intended use, design, principle of operation, technology, materials, specifications and performance to the predicates. |
|---|
Page 9
Submitter: QMAPP®
Fysicon BV Premarket Notification: Traditional 510(k)
510(k) Summary Page 5 of 11
Substantial Equivalence Summary Table
| TRADE NAME > FEATURE | Proposed (modified) Device: QMAPP®, QMAPP® GO, QMAPP® PCM, QMAPP Hemo and QMAPP® Hybrid | Primary Predicate Device: QMAPP®, QMAPP® GO, QMAPP® AP and QMAPP® EP | Secondary Predicate Device: McKesson CardiologyTM Hemo |
|---|---|---|---|
| 510(k) Number | K241766 | K170032 | K131497 |
| Regulation, Product Code and Regulatory Name | Same as primary predicate device | 21 CFR 870.1425, DQK Programmable diagnostic computer 21 CFR 870.2300, MWI Cardiac monitor (including cardiotachometer and rate alarm) | 21 CFR 870.1425, DQK Programmable diagnostic computer 21 CFR 870.2300, MWI Cardiac monitor (including cardiotachometer and rate alarm) |
| Manufacturer | Same as primary predicate device | Fysicon B.V. | McKesson Israel Ltd. |
| Device description summary | Same as primary predicate device | The QMAPP® system offers a complete physiological/ hemodynamic monitoring and reporting system. The system is built from three units: an Amplifier, Live Monitoring CPU and Reporting CPU. The Amplifier Unit has various sensors connected with the patient, e.g. ECG, SpO2 and NiBP. The Amplifier Unit is connected to the Live Monitoring CPU via a dedicated Ethernet connection. The acquired patient information can be visualized on a Live Monitoring CPU. Typically located in the technical room. A software application executed on the Live Monitoring CPU can visualize the patient information. Also the Amplifier Unit can be controlled, i.e. most importantly, set acquisition and filtering parameters for the different sensors, by the Live Monitoring CPU. Optionally | McKesson CardiologyTM Hemo device is a hemodynamic monitoring system for monitoring vital signs, performing measurements and calculations, documenting procedure and patient data and interfacing to other systems and devices during and after procedures in the areas of: cardiology, cardiac catheterization, electrophysiology, radiology, invasive radiology and other areas where patient/ procedural data management is needed. McKesson CardiologyTM Hemo also acquires patient information from other hospital information systems and makes hemodynamic information available to them. It facilitates seamless interfacing with hospital information systems and cardiac image management, archiving and reporting systems. |
Page 10
Submitter: QMAPP®
Fysicon BV Premarket Notification: Traditional 510(k)
510(k) Summary Page 6 of 11
the Monitoring unit can be connected via a dedicated Ethernet connection to a Reporting CPU, typically located in the technical room. On the Reporting CPU a database is installed which facilitates data storage and retrieval. A software application executed on the Reporting CPU serves as a patient data management system. It can be used for analysis, calculation and reporting in various representations of patient information.
The QMAPP® system, can operate standalone or it can be part of a typical hospital network infrastructure. The latter offers the possibility to send or receive information from and to other devices. The software has several communication modules, based on HL7 or DICOM protocols to interface with third party equipment/systems.
McKesson CardiologyTM Hemo incorporates the FDA cleared ARGUS PB vital signs monitoring device (K012226), which provides patient monitoring via; ECG Leads; Invasive Blood Pressure; SpO2; NiBP; Body temperature; Thermal Dilution Cardiac output and CO2.
McKesson CardiologyTM Hemo is composed of: A control and documentation unit (information System) which is used for administration, performing measurements, recording full disclosure, taking samples and entering procedure notes and overall data input and management of the patient and procedure data. A Clinical Unit that incorporates the "Clinical Systems" and the "Front-End" unit (which incorporates the Schiller Argus PB device – K012226). The clinical unit is responsible for acquiring, analyzing and displaying patient vitals and other pertinent clinical dat. The data is displayed on monitors.
| Intended Use/ Indications for Use Statement | QMAPP® is intended to be used by professional healthcare providers for physiological/hemodynamic monitoring. The system may be used to display and analyze surface ECG (Electrocardiogram), respiration, invasive pressures, pulse oximetry (SpO2), End tidal CO2 (EtCO2), fractional flow reserve (FFR), non- invasive blood pressure (NiBP), surface | QMAPP® is intended for use by professional healthcare providers for physiological/ hemodynamic monitoring. The system may be used to display and analyze surface ECG (Electrocardiogram), respiration, invasive pressures, pulse oximetry (SpO2), end tidal CO2 (EtCO2), fractional flow reserve (FFR), non- invasive blood pressure (NiBP), surface | McKesson Cardiology HemoTM is intended for complete physiological/ hemodynamic monitoring, clinical data acquisition, medical image and data processing, and analytical assessment. McKesson CardiologyTM Hemo is also intended for patient/procedural data management, such as documentation, logging, reporting, trending, storing, reviewing, carrying out clinical |
|---|
Page 11
Submitter: QMAPP®
Fysicon BV Premarket Notification: Traditional 510(k)
510(k) Summary Page 7 of 11
| body temperature, cardiac output and intra-cardiac ECG. QMAPP® provides also clinical data acquisition, medical image/data processing and analytical assessment. QMAPP® is intended for use in the areas of, but not limited to cardiology, cardiac catheterization, electrophysiology, radiology, invasive radiology. QMAPP® can be used standalone and in networked environments. The system is intended for patient/procedural data management, such as documentation, logging, reporting, trending, storing, reviewing, carrying out clinical calculations and exporting various representations of the acquired data. Data may also be acquired from and/or send to other devices, such as physiological monitoring system, information management systems, image acquisition/storage devices and other medical devices. | body temperature, cardiac output and intra-cardiac ECG. QMAPP® is intended to be used on the patient population of adults. QMAPP® provides also clinical data acquisition, medical image/data processing and analytical assessment. QMAPP® is intended for use in the areas of, but not limited to cardiology, cardiac catheterization, electro- physiology, radiology, invasive radiology. QMAPP® can be used standalone and in networked environments. The system is intended for patient/ procedural data management, such as documentation, logging, reporting, trending, storing, reviewing, carrying out clinical calculations and exporting various representations of the acquired data. Data may also be acquired from and/or send to other devices, such as physiological monitoring system, information management systems, image acquisition/storage devices and other medical devices. | calculations and exporting various representations of the acquired data. Data may also be acquired from and/or sent to other devices, such as physiological monitoring systems, information management systems, image acquisition/storage devices, and other medical devices. McKesson CardiologyTM Hemo is intended for use in the areas of: cardiology, cardiac catheterization, electrophysiology, radiology, invasive radiology, and other areas where patient/procedural data management is needed. User-adjustable alarms (both visual and audible) available in the system alert the operator to anomalous occurrences and facilitate timely responses. Use of the system is not intended for unattended patient monitoring or in situations where arrhythmia detection is required. | |
|---|---|---|---|
| Intended Populations | No restrictions or limitations | Adults | No restrictions or limitations |
| Dimensions | Same as primary predicate device | 298 x 233 x 47 mm 11.7 x 9.2 x 1.9 inch | 280 x 135 x 130 mm 11.0 x 5.3 x 5.1 inch |
Page 12
Submitter: QMAPP®
Fysicon BV Premarket Notification: Traditional 510(k)
510(k) Summary Page 8 of 11
| Premarket Notification: Traditional 510(k) | QMAPP® | ||
|---|---|---|---|
| Weight | Same as primary predicate device | 2200 grams 4.85 pounds | 3800 grams 8.38 pounds |
| Energy source | Same as primary predicate device | 90 - 264V 24V DC at tableside | 100-264V 24V at tableside |
| Amplifier – Monitor CPU | Same as primary predicate device | 100 Mbit RS232 | |
| Monitor CPU – Reporting CPU | Same as primary predicate device | 100 MB | 100 MB |
| CPU LAN | Same as primary predicate device | Intel i5, 2.00 GHz | > Intel Pentium 4 |
| Data sent to central server | Same as primary predicate device | Yes, if a networked system is chosen | Yes, if a networked system is chosen |
| MONITORS SURFACE ECG | Same as primary predicate device | Yes | Yes |
| Method | Same as primary predicate device | ECG lead wires attached to disposable electrodes to the skin | ECG lead wires attached to disposable electrodes to the skin |
| Resolution | Same as primary predicate device | 24 bit | 12 bit |
| Input impedance | Same as primary predicate device | > 2.5 MOhm | > 2.5 MOhm |
| Common mode rejection | Same as primary predicate device | > 100 dB | > 100 dB |
| Sampling frequency | Same as primary predicate device | 2 – 32 KHz | 1 KHz |
| Channels | Same as primary predicate device | 12 | 12 |
| MONITORS HEART RATE | Same as primary predicate device | Yes | Yes |
| Method | Same as primary predicate device | QRS detection | QRS detection |
| HR range | Same as secondary predicate device | 15 – 300 bpm | 15 – 350 bpm |
| Accuracy | Same as primary predicate device | ± 2% | ± 2% |
Page 13
Submitter: QMAPP®
Fysicon BV Premarket Notification: Traditional 510(k)
510(k) Summary Page 9 of 11
| Premarket Notification: Traditional 510(k) | QMAPP® | ||
|---|---|---|---|
| MONITORS RESPIRATION EFFORT | Same as primary predicate device | Yes | Yes |
| Method | Same as primary predicate device | Impedance Pneumography | Impedance Pneumography |
| Resolution | Same as primary predicate device | 1/min | 1/min |
| Range | Same as primary predicate device | 0 – 150 / Min | 0 – 200 / Min |
| Channels | Same as primary predicate device | 1 | 1 |
| MONITORS NIBP | Same as primary predicate device | Yes | Yes |
| Method | Same as primary predicate device | Oscillometric (CAS Max module) | Oscillometric |
| Range | Same as primary predicate device | 15 - 260 mm Hg | 15 – 200 mm Hg |
| Accuracy | Same as primary predicate device | ± 5 mm Hg | ± 5 mm Hg |
| (Third party) Module | Same as primary predicate device | CAS Medical Systems, 740 Select, (K150620) | Part of device: ARGUS PB vital signs monitoring Device, (K012226), |
| MONITORS OXYGEN SATURATION | Same as primary predicate device | Yes | Yes |
| Method | Same as primary predicate device | Nellcor Oximax | Masimo Set |
| Range | Same as primary predicate device | 1 -100% | 1 – 100% |
| Accuracy | Same as primary predicate device | ± 1% | ± 3% |
| Channels | Same as primary predicate device | 1 | 1 |
| (Third party) Module | Same as primary predicate device | OxiMax N-600x Pulse Oximeter (K083325) | Part of device ARGUS PB-1000 Masimo Set (K012226), |
| MONITORS IBP | Same as primary predicate device | Yes | Yes |
| Method | Same as primary predicate device | Pressure transducer | Pressure transducer |
| Accuracy | Same as primary predicate device | ± 2 mm Hg or ± 1 % | ± 2 mm Hg or ± 1 % |
Page 14
Submitter: QMAPP®
Fysicon BV Premarket Notification: Traditional 510(k)
510(k) Summary Page 10 of 11
| Premarket Notification: Traditional 510(k) | QMAPP® | ||
|---|---|---|---|
| Range | Same as primary predicate device | -30 - 320 mm Hg | - 400 – 400 mm Hg |
| Channels | Same as primary predicate device | 4 | 4 |
| MONITORS SKIN TEMPERATURE | Same as primary predicate device | Yes | Yes |
| Method | Same as primary predicate device | Thermistor, YSI compatible | Thermistor, YSI compatible |
| Range | Same as primary predicate device | 20° – 45° C 68° – 113° F | 15° – 45° C 59° – 113° F |
| Accuracy | Same as primary predicate device | ± 0.1° C ± 0.18° F | ± 0.1° C ± 0.18° F |
| Channels | Same as primary predicate device | 2 | 1 |
| MONITORS CARDIAC OUTPUT | Same as primary predicate device | Yes | Yes |
| Method | Same as primary predicate device | Thermo Dilution and (calculated) FICK | Thermo Dilution and (calculated) FICK |
| Range | Same as primary predicate device | 0.1 – 20 L | 0.1 – 20 L |
| Accuracy | Same as primary predicate device | ± 0.1 L | ± 0.1 L |
| MONITORS EtCO2 | Same as primary predicate device | Yes | Yes |
| Method | Same as primary predicate device | Low flow Side stream | Low Flow Side stream |
| CO2 resolution | Same as primary predicate device | 0.1 mm Hg 0 to 49 mm Hg 0.2 mm Hg 49 to 152 mm Hg | 0.1 mm Hg 0 to 69 mm Hg 0.25 mm Hg 70 to 150 mm Hg |
| CO2 Accuracy | Same as primary predicate device | 0 – 40 mm Hg, ± 2 mm Hg; 41 – 70 mm Hg, ± 5%; 71-100 mm Hg, ± 8%; >101 10% | 0– 40mmHg ±2 mm Hg 41– 70mmHg ±5% 71–100mmHg ±8% 101–150mmHg ±10% Above 80 BPM ±12% |
| (Third party) Module | Same as primary predicate device | GoldWEI C300 | Part of device CLEO Patient Monitor, (K142244) Respironics Capnostat 5 sensor, (K042601) |
Page 15
Submitter: QMAPP®
Fysicon BV Premarket Notification: Traditional 510(k)
510(k) Summary Page 11 of 11
| Premarket Notification: Traditional 510(k) | QMAPP® | ||
|---|---|---|---|
| MONITORS Intra Cardiac ECG | Same as primary predicate device | Yes | No |
| Method | Same as primary predicate device | Electro Physiology catheter | n/a |
| Resolution | Same as primary predicate device | 24 Bit | n/a |
| Input impedance | Same as primary predicate device | > 2.5 MOhm | n/a |
| Common mode rejection | Same as primary predicate device | > 100 dB | n/a |
| HR range | Same as primary predicate device | 15 – 300 bpm | n/a |
| Sampling frequency | Same as primary predicate device | 2 - 32 kHz | n/a |
| Channels | Same as primary predicate device | 8, 16 or 32 (bipolar) Channels | 0 |
§ 870.2300 Cardiac monitor (including cardiotachometer and rate alarm).
(a)
Identification. A cardiac monitor (including cardiotachometer and rate alarm) is a device used to measure the heart rate from an analog signal produced by an electrocardiograph, vectorcardiograph, or blood pressure monitor. This device may sound an alarm when the heart rate falls outside preset upper and lower limits.(b)
Classification. Class II (performance standards).